These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 16217102)

  • 1. Inconclusive evidence puts Adderall back on the market.
    Kondro W
    CMAJ; 2005 Oct; 173(8):858. PubMed ID: 16217102
    [No Abstract]   [Full Text] [Related]  

  • 2. Adderall and other drugs for attention-deficit/hyperactivity disorder.
    Med Lett Drugs Ther; 1994 Nov; 36(936):109-10. PubMed ID: 7968783
    [No Abstract]   [Full Text] [Related]  

  • 3. Adderall: the newest available option in ADHD.
    Adv Nurse Pract; 1997 Jun; 5(6):73-4. PubMed ID: 9459934
    [No Abstract]   [Full Text] [Related]  

  • 4. Adderall, the atypicals, and weight gain.
    Horrigan JP; Barnhill LJ; Kohli RR
    J Am Acad Child Adolesc Psychiatry; 2001 Jun; 40(6):620. PubMed ID: 11392337
    [No Abstract]   [Full Text] [Related]  

  • 5. ECGs before stimulants in children.
    Med Lett Drugs Ther; 2008 Jul; 50(1291):60. PubMed ID: 18654112
    [No Abstract]   [Full Text] [Related]  

  • 6. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
    Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT
    Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Winterstein AG; Gerhard T; Shuster J; Johnson M; Zito JM; Saidi A
    Pediatrics; 2007 Dec; 120(6):e1494-501. PubMed ID: 18055666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adderall in the land of Oz.
    Hammerschlag C
    Caring; 2013; 32(2):55. PubMed ID: 23697076
    [No Abstract]   [Full Text] [Related]  

  • 9. Medications for attention deficit hyperactivity disorder: cardiovascular concerns.
    Wooltorton E
    CMAJ; 2006 Jul; 175(1):29. PubMed ID: 16772535
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder.
    Wigal SB; McGough JJ; McCracken JT; Biederman J; Spencer TJ; Posner KL; Wigal TL; Kollins SH; Clark TM; Mays DA; Zhang Y; Tulloch SJ
    J Atten Disord; 2005 Aug; 9(1):275-89. PubMed ID: 16371674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Adderall in ADHD.
    Diller LH
    J Am Acad Child Adolesc Psychiatry; 1999 Jan; 38(1):2. PubMed ID: 9893403
    [No Abstract]   [Full Text] [Related]  

  • 13. US senator alleges FDA tried to prevent Adderall XR withdrawal in Canada.
    Eggertson L
    CMAJ; 2005 Mar; 172(7):865. PubMed ID: 15758187
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of Adderall for Attention-Deficit/Hyperactivity Disorder: a meta-analysis.
    Faraone SV; Biederman J
    J Atten Disord; 2002 Sep; 6(2):69-75. PubMed ID: 12142863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adderall and seizures.
    Thomas S; Upadhyaya H
    J Am Acad Child Adolesc Psychiatry; 2002 Apr; 41(4):365. PubMed ID: 11931590
    [No Abstract]   [Full Text] [Related]  

  • 16. Stimulants and sudden death: what is a physician to do?
    Wilens TE; Prince JB; Spencer TJ; Biederman J
    Pediatrics; 2006 Sep; 118(3):1215-9. PubMed ID: 16951018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attention-deficit/hyperactivity disorder in pediatric patients with epilepsy: review of pharmacological treatment.
    Torres AR; Whitney J; Gonzalez-Heydrich J
    Epilepsy Behav; 2008 Feb; 12(2):217-33. PubMed ID: 18065271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pemoline (Cylert): market withdrawal.
    Hogan V
    CMAJ; 2000 Jan; 162(1):106, 110. PubMed ID: 11216184
    [No Abstract]   [Full Text] [Related]  

  • 19. Myocardial infarction in an adolescent taking Adderall.
    Gandhi PJ; Ezeala GU; Luyen TT; Tu TC; Tran MT
    Am J Health Syst Pharm; 2005 Jul; 62(14):1494-7. PubMed ID: 15998931
    [No Abstract]   [Full Text] [Related]  

  • 20. Forecasting three-month outcomes in a laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children With ADHD.
    Faraone SV; Wigal SB; Hodgkins P
    J Atten Disord; 2007 Jul; 11(1):74-82. PubMed ID: 17606774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.